Encephalopathy (Central Nervous System) - Drugs in Development, 2021

November 2021 | 113 pages | ID: E26C485464EDEN
Global Markets Direct

Abstracts

Encephalopathy (Central Nervous System) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalopathy - Drugs In Development, 2021, provides an overview of the Encephalopathy (Central Nervous System) pipeline landscape.

Encephalopathy is a term for any diffuse disease of the brain that alters brain function or structure. Symptoms include seizures, difficulty speaking or swallowing, trembling, involuntary twitching and muscle weakness. Causes include traumas or injuries, genetic, liver disease, hypoxic condition, Lyme disease and organ failure.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Encephalopathy - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Encephalopathy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Encephalopathy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 2, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Encephalopathy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalopathy (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Encephalopathy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Encephalopathy (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Encephalopathy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Encephalopathy (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Encephalopathy (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Encephalopathy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Encephalopathy - Overview
Encephalopathy - Therapeutics Development
Encephalopathy - Therapeutics Assessment
Encephalopathy - Companies Involved in Therapeutics Development
Encephalopathy - Drug Profiles
Encephalopathy - Dormant Projects
Encephalopathy - Discontinued Products
Encephalopathy - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Encephalopathy, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Encephalopathy - Pipeline by Argenica Therapeutics Ltd, 2021
Encephalopathy - Pipeline by Biom Therapeutics LLC, 2021
Encephalopathy - Pipeline by BrainRepair UG, 2021
Encephalopathy - Pipeline by F. Hoffmann-La Roche Ltd, 2021
Encephalopathy - Pipeline by Gene Therapy Research Institution Co Ltd, 2021
Encephalopathy - Pipeline by Hope Biosciences LLC, 2021
Encephalopathy - Pipeline by Jazz Pharmaceuticals Plc, 2021
Encephalopathy - Pipeline by JS Genetics Inc, 2021
Encephalopathy - Pipeline by Mesoblast Ltd, 2021
Encephalopathy - Pipeline by Mithra Pharmaceuticals SA, 2021
Encephalopathy - Pipeline by Mononuclear Therapeutics Ltd, 2021
Encephalopathy - Pipeline by Orphan Star Therapeutics LLC, 2021
Encephalopathy - Pipeline by Pfizer Inc, 2021
Encephalopathy - Pipeline by ProThera Biologics Inc, 2021
Encephalopathy - Pipeline by ReAlta Life Sciences Inc, 2021
Encephalopathy - Pipeline by Rohto Pharmaceutical Co Ltd, 2021
Encephalopathy - Pipeline by SL Bigen Inc, 2021
Encephalopathy - Pipeline by Worphmed Srl, 2021
Encephalopathy - Dormant Projects, 2021
Encephalopathy - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Encephalopathy, 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021